Loading…

Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions

Background GATA‐3 is a transcription factor involved in human tissue growth and differentiation. It is a potential marker for breast carcinoma origin in metastasis and predictive of good prognosis. We aim to evaluate the role of GATA3 in determining the breast origin of metastatic adenocarcinoma in...

Full description

Saved in:
Bibliographic Details
Published in:Diagnostic cytopathology 2016-09, Vol.44 (9), p.731-736
Main Authors: El Hag, Mohamed I., Ha, Jennifer, Farag, Rosemary, El Hag, Amani M., Michael, Claire W.
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c1761-b8e04e14b3e841d0a2e689f383e451fafea1ba25523d6d43f2f88d845ae6ad663
cites
container_end_page 736
container_issue 9
container_start_page 731
container_title Diagnostic cytopathology
container_volume 44
creator El Hag, Mohamed I.
Ha, Jennifer
Farag, Rosemary
El Hag, Amani M.
Michael, Claire W.
description Background GATA‐3 is a transcription factor involved in human tissue growth and differentiation. It is a potential marker for breast carcinoma origin in metastasis and predictive of good prognosis. We aim to evaluate the role of GATA3 in determining the breast origin of metastatic adenocarcinoma in malignant effusions using immunohistochemistry on cell‐block microarray in comparison with ER and PR results. Methods Cell blocks from 100 cases of malignant and reactive serous effusions with confirmed diagnosis were selected; 28 mammary carcinomas, 64 extra‐mammary adenocarcinomas (gastrointestinal, pulmonary, gynecologic), and 8 reactive mesothelium proliferation as control. Immunohistochemistry on cell‐block microarray was used. Microarray slides were stained for GATA‐3, ER and PR. Nuclear staining of >1% was considered positive. Results GATA3, ER and PR were positive in 25 (89%), 20 (71%) and 16 (57%) of breast carcinoma cases, respectively. All non‐breast cancer cases were negative for GATA‐3 with the exception of one Müllerian adenocarcinoma (1.6%). The calculated sensitivity, specificity and positive predictive value (PPV) of GATA3 reactivity in determining the breast origin of metastatic adenocarcinoma was 89.3% (95% CI: 71.7–97.7%), 98.6% (95% CI: 91.6–99.9%) and 96.2% (95% CI: 80.4–99.9%), respectively. GATA3 positivity was associated with ER or PR positivity in 84% of cases. Conclusions GATA3 is a useful marker in determining the breast origin of metastatic adenocarcinoma in malignant serous effusions. Reactivity to GATA3 may indicate good prognosis. Diagn. Cytopathol. 2016;44:731–736. © 2016 Wiley Periodicals, Inc.
doi_str_mv 10.1002/dc.23521
format article
fullrecord <record><control><sourceid>proquest_wiley</sourceid><recordid>TN_cdi_proquest_miscellaneous_1811895285</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1811895285</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1761-b8e04e14b3e841d0a2e689f383e451fafea1ba25523d6d43f2f88d845ae6ad663</originalsourceid><addsrcrecordid>eNpd0FFrFDEQB_AgFjxbwY8Q8MWXbTOZzW728Tj1FEq15Q4fQ24z0bR7yZnsUe_bu3ctCj79GebH8GcYewviEoSQV66_lKgkvGAzEF1bCcTuJZvpVqkKBHav2OtS7oUQnYRmxob1GIYwHnjyfDlfzSvkIfLxJ_HHlB-q9e642GSyZeTWUUy9zX2IaWu5jY6HsXAXvKdMcQx2mAb7I6YSyvFMoZz2hZP3-xJSLBfszNuh0JvnPGfrTx9Xi8_V9dfll8X8uuqhbaDaaBI1Qb1B0jU4YSU1uvOokWoF3nqysLFSKYmucTV66bV2ulaWGuuaBs_Z-6e7u5x-7amMZhtKT8NgI02FDGgA3Smp1UTf_Ufv0z7Hqd1JIWgEnFT1pB7DQAezy2Fr88GAMMefG9eb08_Nh8Up__lQRvr919v8YJoWW2W-3yzNqsblzbfVrbnDP16ShDU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1811318313</pqid></control><display><type>article</type><title>Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>El Hag, Mohamed I. ; Ha, Jennifer ; Farag, Rosemary ; El Hag, Amani M. ; Michael, Claire W.</creator><creatorcontrib>El Hag, Mohamed I. ; Ha, Jennifer ; Farag, Rosemary ; El Hag, Amani M. ; Michael, Claire W.</creatorcontrib><description>Background GATA‐3 is a transcription factor involved in human tissue growth and differentiation. It is a potential marker for breast carcinoma origin in metastasis and predictive of good prognosis. We aim to evaluate the role of GATA3 in determining the breast origin of metastatic adenocarcinoma in malignant effusions using immunohistochemistry on cell‐block microarray in comparison with ER and PR results. Methods Cell blocks from 100 cases of malignant and reactive serous effusions with confirmed diagnosis were selected; 28 mammary carcinomas, 64 extra‐mammary adenocarcinomas (gastrointestinal, pulmonary, gynecologic), and 8 reactive mesothelium proliferation as control. Immunohistochemistry on cell‐block microarray was used. Microarray slides were stained for GATA‐3, ER and PR. Nuclear staining of &gt;1% was considered positive. Results GATA3, ER and PR were positive in 25 (89%), 20 (71%) and 16 (57%) of breast carcinoma cases, respectively. All non‐breast cancer cases were negative for GATA‐3 with the exception of one Müllerian adenocarcinoma (1.6%). The calculated sensitivity, specificity and positive predictive value (PPV) of GATA3 reactivity in determining the breast origin of metastatic adenocarcinoma was 89.3% (95% CI: 71.7–97.7%), 98.6% (95% CI: 91.6–99.9%) and 96.2% (95% CI: 80.4–99.9%), respectively. GATA3 positivity was associated with ER or PR positivity in 84% of cases. Conclusions GATA3 is a useful marker in determining the breast origin of metastatic adenocarcinoma in malignant serous effusions. Reactivity to GATA3 may indicate good prognosis. Diagn. Cytopathol. 2016;44:731–736. © 2016 Wiley Periodicals, Inc.</description><identifier>ISSN: 8755-1039</identifier><identifier>EISSN: 1097-0339</identifier><identifier>DOI: 10.1002/dc.23521</identifier><language>eng</language><publisher>Hoboken: Blackwell Publishing Ltd</publisher><subject>adenocarcinoma ; breast ; GATA-3 ; malignant effusion ; serous fluid</subject><ispartof>Diagnostic cytopathology, 2016-09, Vol.44 (9), p.731-736</ispartof><rights>2016 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1761-b8e04e14b3e841d0a2e689f383e451fafea1ba25523d6d43f2f88d845ae6ad663</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>El Hag, Mohamed I.</creatorcontrib><creatorcontrib>Ha, Jennifer</creatorcontrib><creatorcontrib>Farag, Rosemary</creatorcontrib><creatorcontrib>El Hag, Amani M.</creatorcontrib><creatorcontrib>Michael, Claire W.</creatorcontrib><title>Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions</title><title>Diagnostic cytopathology</title><addtitle>Diagn. Cytopathol</addtitle><description>Background GATA‐3 is a transcription factor involved in human tissue growth and differentiation. It is a potential marker for breast carcinoma origin in metastasis and predictive of good prognosis. We aim to evaluate the role of GATA3 in determining the breast origin of metastatic adenocarcinoma in malignant effusions using immunohistochemistry on cell‐block microarray in comparison with ER and PR results. Methods Cell blocks from 100 cases of malignant and reactive serous effusions with confirmed diagnosis were selected; 28 mammary carcinomas, 64 extra‐mammary adenocarcinomas (gastrointestinal, pulmonary, gynecologic), and 8 reactive mesothelium proliferation as control. Immunohistochemistry on cell‐block microarray was used. Microarray slides were stained for GATA‐3, ER and PR. Nuclear staining of &gt;1% was considered positive. Results GATA3, ER and PR were positive in 25 (89%), 20 (71%) and 16 (57%) of breast carcinoma cases, respectively. All non‐breast cancer cases were negative for GATA‐3 with the exception of one Müllerian adenocarcinoma (1.6%). The calculated sensitivity, specificity and positive predictive value (PPV) of GATA3 reactivity in determining the breast origin of metastatic adenocarcinoma was 89.3% (95% CI: 71.7–97.7%), 98.6% (95% CI: 91.6–99.9%) and 96.2% (95% CI: 80.4–99.9%), respectively. GATA3 positivity was associated with ER or PR positivity in 84% of cases. Conclusions GATA3 is a useful marker in determining the breast origin of metastatic adenocarcinoma in malignant serous effusions. Reactivity to GATA3 may indicate good prognosis. Diagn. Cytopathol. 2016;44:731–736. © 2016 Wiley Periodicals, Inc.</description><subject>adenocarcinoma</subject><subject>breast</subject><subject>GATA-3</subject><subject>malignant effusion</subject><subject>serous fluid</subject><issn>8755-1039</issn><issn>1097-0339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpd0FFrFDEQB_AgFjxbwY8Q8MWXbTOZzW728Tj1FEq15Q4fQ24z0bR7yZnsUe_bu3ctCj79GebH8GcYewviEoSQV66_lKgkvGAzEF1bCcTuJZvpVqkKBHav2OtS7oUQnYRmxob1GIYwHnjyfDlfzSvkIfLxJ_HHlB-q9e642GSyZeTWUUy9zX2IaWu5jY6HsXAXvKdMcQx2mAb7I6YSyvFMoZz2hZP3-xJSLBfszNuh0JvnPGfrTx9Xi8_V9dfll8X8uuqhbaDaaBI1Qb1B0jU4YSU1uvOokWoF3nqysLFSKYmucTV66bV2ulaWGuuaBs_Z-6e7u5x-7amMZhtKT8NgI02FDGgA3Smp1UTf_Ufv0z7Hqd1JIWgEnFT1pB7DQAezy2Fr88GAMMefG9eb08_Nh8Up__lQRvr919v8YJoWW2W-3yzNqsblzbfVrbnDP16ShDU</recordid><startdate>201609</startdate><enddate>201609</enddate><creator>El Hag, Mohamed I.</creator><creator>Ha, Jennifer</creator><creator>Farag, Rosemary</creator><creator>El Hag, Amani M.</creator><creator>Michael, Claire W.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>K9.</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>201609</creationdate><title>Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions</title><author>El Hag, Mohamed I. ; Ha, Jennifer ; Farag, Rosemary ; El Hag, Amani M. ; Michael, Claire W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1761-b8e04e14b3e841d0a2e689f383e451fafea1ba25523d6d43f2f88d845ae6ad663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>adenocarcinoma</topic><topic>breast</topic><topic>GATA-3</topic><topic>malignant effusion</topic><topic>serous fluid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>El Hag, Mohamed I.</creatorcontrib><creatorcontrib>Ha, Jennifer</creatorcontrib><creatorcontrib>Farag, Rosemary</creatorcontrib><creatorcontrib>El Hag, Amani M.</creatorcontrib><creatorcontrib>Michael, Claire W.</creatorcontrib><collection>Istex</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Diagnostic cytopathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>El Hag, Mohamed I.</au><au>Ha, Jennifer</au><au>Farag, Rosemary</au><au>El Hag, Amani M.</au><au>Michael, Claire W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions</atitle><jtitle>Diagnostic cytopathology</jtitle><addtitle>Diagn. Cytopathol</addtitle><date>2016-09</date><risdate>2016</risdate><volume>44</volume><issue>9</issue><spage>731</spage><epage>736</epage><pages>731-736</pages><issn>8755-1039</issn><eissn>1097-0339</eissn><abstract>Background GATA‐3 is a transcription factor involved in human tissue growth and differentiation. It is a potential marker for breast carcinoma origin in metastasis and predictive of good prognosis. We aim to evaluate the role of GATA3 in determining the breast origin of metastatic adenocarcinoma in malignant effusions using immunohistochemistry on cell‐block microarray in comparison with ER and PR results. Methods Cell blocks from 100 cases of malignant and reactive serous effusions with confirmed diagnosis were selected; 28 mammary carcinomas, 64 extra‐mammary adenocarcinomas (gastrointestinal, pulmonary, gynecologic), and 8 reactive mesothelium proliferation as control. Immunohistochemistry on cell‐block microarray was used. Microarray slides were stained for GATA‐3, ER and PR. Nuclear staining of &gt;1% was considered positive. Results GATA3, ER and PR were positive in 25 (89%), 20 (71%) and 16 (57%) of breast carcinoma cases, respectively. All non‐breast cancer cases were negative for GATA‐3 with the exception of one Müllerian adenocarcinoma (1.6%). The calculated sensitivity, specificity and positive predictive value (PPV) of GATA3 reactivity in determining the breast origin of metastatic adenocarcinoma was 89.3% (95% CI: 71.7–97.7%), 98.6% (95% CI: 91.6–99.9%) and 96.2% (95% CI: 80.4–99.9%), respectively. GATA3 positivity was associated with ER or PR positivity in 84% of cases. Conclusions GATA3 is a useful marker in determining the breast origin of metastatic adenocarcinoma in malignant serous effusions. Reactivity to GATA3 may indicate good prognosis. Diagn. Cytopathol. 2016;44:731–736. © 2016 Wiley Periodicals, Inc.</abstract><cop>Hoboken</cop><pub>Blackwell Publishing Ltd</pub><doi>10.1002/dc.23521</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 8755-1039
ispartof Diagnostic cytopathology, 2016-09, Vol.44 (9), p.731-736
issn 8755-1039
1097-0339
language eng
recordid cdi_proquest_miscellaneous_1811895285
source Wiley-Blackwell Read & Publish Collection
subjects adenocarcinoma
breast
GATA-3
malignant effusion
serous fluid
title Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T15%3A51%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Utility%20of%20GATA-3%20in%20the%20work-Up%20of%20breast%20adenocarcinoma%20and%20its%20differential%20diagnosis%20in%20serous%20effusions&rft.jtitle=Diagnostic%20cytopathology&rft.au=El%20Hag,%20Mohamed%20I.&rft.date=2016-09&rft.volume=44&rft.issue=9&rft.spage=731&rft.epage=736&rft.pages=731-736&rft.issn=8755-1039&rft.eissn=1097-0339&rft_id=info:doi/10.1002/dc.23521&rft_dat=%3Cproquest_wiley%3E1811895285%3C/proquest_wiley%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1761-b8e04e14b3e841d0a2e689f383e451fafea1ba25523d6d43f2f88d845ae6ad663%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1811318313&rft_id=info:pmid/&rfr_iscdi=true